Drug firm Roche has launched Emicizumab under the brand name Hemlibra in India for preventive treatment of Hemophilia A, an inherited disorder in which a person’s blood does not clot properly. Hemlibra is the first weekly subcutaneous prophylaxis injection shown to prevent or reduce the frequency of bleeding episodes and improve the quality of life, Roche said in a statement. All current prophylactic treatment options for people with Hemophilia A with factor VIII inhibitors require intravenous infusions several times a week, it added.

Related Topics